Dendritic cells in cancer immunotherapy: Vaccines or autologous transplants?

Pawel Kalinski, Howard Edington, Herbert J. Zeh, Hideho Okada, Lisa H. Butterfield, John M. Kirkwood, David L. Bartlett

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Dendritic cells (DCs) are the most powerful immunostimulatory cells specialized in the induction and regulation of immune responses. Their properties and the feasibility of their large-scale ex vivo generation led to the application of ex vivo-educated DCs to bypass the dysfunction of endogenous DCs in cancer patients and to induce therapeutic anti-cancer immunity. While multiple paradigms of therapeutic application of DCs reflect their consideration as cancer "vaccines", numerous features of DC-based vaccination resemble those of autologous transplants, resulting in challenges and opportunities that distinguish them from classical vaccines. In addition to the functional heterogeneity of DC subsets and plasticity of the individual DC types, the unique features of DCs are the kinetic character of their function, limited functional stability, and the possibility to imprint in maturing DCs distinct functions relevant for the induction of effective cancer immunity, such as the induction of different effector functions or different homing properties of tumor-specific T cells (delivery of "signal 3" and "signal 4"). These considerations highlight the importance of the application of optimized, potentially patient-specific conditions of ex vivo culture of DCs and their delivery, with the logistic and regulatory implications shared with transplantation and other surgical procedures.

Original languageEnglish (US)
Pages (from-to)235-247
Number of pages13
JournalImmunologic Research
Volume50
Issue number2-3
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Cancer Vaccines
Autografts
Immunotherapy
Dendritic Cells
Immunity
Neoplasms
Vaccination
Vaccines
Transplantation
T-Lymphocytes

Keywords

  • Cancer
  • Chemokine receptors
  • Chemokines
  • CTL
  • Cytokines
  • Dendritic cells
  • IL-12
  • Immunotherapy
  • NK
  • Th1
  • Treg
  • Vaccines

ASJC Scopus subject areas

  • Immunology

Cite this

Kalinski, P., Edington, H., Zeh, H. J., Okada, H., Butterfield, L. H., Kirkwood, J. M., & Bartlett, D. L. (2011). Dendritic cells in cancer immunotherapy: Vaccines or autologous transplants? Immunologic Research, 50(2-3), 235-247. https://doi.org/10.1007/s12026-011-8224-z

Dendritic cells in cancer immunotherapy : Vaccines or autologous transplants? / Kalinski, Pawel; Edington, Howard; Zeh, Herbert J.; Okada, Hideho; Butterfield, Lisa H.; Kirkwood, John M.; Bartlett, David L.

In: Immunologic Research, Vol. 50, No. 2-3, 01.08.2011, p. 235-247.

Research output: Contribution to journalArticle

Kalinski, P, Edington, H, Zeh, HJ, Okada, H, Butterfield, LH, Kirkwood, JM & Bartlett, DL 2011, 'Dendritic cells in cancer immunotherapy: Vaccines or autologous transplants?', Immunologic Research, vol. 50, no. 2-3, pp. 235-247. https://doi.org/10.1007/s12026-011-8224-z
Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM et al. Dendritic cells in cancer immunotherapy: Vaccines or autologous transplants? Immunologic Research. 2011 Aug 1;50(2-3):235-247. https://doi.org/10.1007/s12026-011-8224-z
Kalinski, Pawel ; Edington, Howard ; Zeh, Herbert J. ; Okada, Hideho ; Butterfield, Lisa H. ; Kirkwood, John M. ; Bartlett, David L. / Dendritic cells in cancer immunotherapy : Vaccines or autologous transplants?. In: Immunologic Research. 2011 ; Vol. 50, No. 2-3. pp. 235-247.
@article{a797f2f463494b60ac727b9d567bea96,
title = "Dendritic cells in cancer immunotherapy: Vaccines or autologous transplants?",
abstract = "Dendritic cells (DCs) are the most powerful immunostimulatory cells specialized in the induction and regulation of immune responses. Their properties and the feasibility of their large-scale ex vivo generation led to the application of ex vivo-educated DCs to bypass the dysfunction of endogenous DCs in cancer patients and to induce therapeutic anti-cancer immunity. While multiple paradigms of therapeutic application of DCs reflect their consideration as cancer {"}vaccines{"}, numerous features of DC-based vaccination resemble those of autologous transplants, resulting in challenges and opportunities that distinguish them from classical vaccines. In addition to the functional heterogeneity of DC subsets and plasticity of the individual DC types, the unique features of DCs are the kinetic character of their function, limited functional stability, and the possibility to imprint in maturing DCs distinct functions relevant for the induction of effective cancer immunity, such as the induction of different effector functions or different homing properties of tumor-specific T cells (delivery of {"}signal 3{"} and {"}signal 4{"}). These considerations highlight the importance of the application of optimized, potentially patient-specific conditions of ex vivo culture of DCs and their delivery, with the logistic and regulatory implications shared with transplantation and other surgical procedures.",
keywords = "Cancer, Chemokine receptors, Chemokines, CTL, Cytokines, Dendritic cells, IL-12, Immunotherapy, NK, Th1, Treg, Vaccines",
author = "Pawel Kalinski and Howard Edington and Zeh, {Herbert J.} and Hideho Okada and Butterfield, {Lisa H.} and Kirkwood, {John M.} and Bartlett, {David L.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1007/s12026-011-8224-z",
language = "English (US)",
volume = "50",
pages = "235--247",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "2-3",

}

TY - JOUR

T1 - Dendritic cells in cancer immunotherapy

T2 - Vaccines or autologous transplants?

AU - Kalinski, Pawel

AU - Edington, Howard

AU - Zeh, Herbert J.

AU - Okada, Hideho

AU - Butterfield, Lisa H.

AU - Kirkwood, John M.

AU - Bartlett, David L.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Dendritic cells (DCs) are the most powerful immunostimulatory cells specialized in the induction and regulation of immune responses. Their properties and the feasibility of their large-scale ex vivo generation led to the application of ex vivo-educated DCs to bypass the dysfunction of endogenous DCs in cancer patients and to induce therapeutic anti-cancer immunity. While multiple paradigms of therapeutic application of DCs reflect their consideration as cancer "vaccines", numerous features of DC-based vaccination resemble those of autologous transplants, resulting in challenges and opportunities that distinguish them from classical vaccines. In addition to the functional heterogeneity of DC subsets and plasticity of the individual DC types, the unique features of DCs are the kinetic character of their function, limited functional stability, and the possibility to imprint in maturing DCs distinct functions relevant for the induction of effective cancer immunity, such as the induction of different effector functions or different homing properties of tumor-specific T cells (delivery of "signal 3" and "signal 4"). These considerations highlight the importance of the application of optimized, potentially patient-specific conditions of ex vivo culture of DCs and their delivery, with the logistic and regulatory implications shared with transplantation and other surgical procedures.

AB - Dendritic cells (DCs) are the most powerful immunostimulatory cells specialized in the induction and regulation of immune responses. Their properties and the feasibility of their large-scale ex vivo generation led to the application of ex vivo-educated DCs to bypass the dysfunction of endogenous DCs in cancer patients and to induce therapeutic anti-cancer immunity. While multiple paradigms of therapeutic application of DCs reflect their consideration as cancer "vaccines", numerous features of DC-based vaccination resemble those of autologous transplants, resulting in challenges and opportunities that distinguish them from classical vaccines. In addition to the functional heterogeneity of DC subsets and plasticity of the individual DC types, the unique features of DCs are the kinetic character of their function, limited functional stability, and the possibility to imprint in maturing DCs distinct functions relevant for the induction of effective cancer immunity, such as the induction of different effector functions or different homing properties of tumor-specific T cells (delivery of "signal 3" and "signal 4"). These considerations highlight the importance of the application of optimized, potentially patient-specific conditions of ex vivo culture of DCs and their delivery, with the logistic and regulatory implications shared with transplantation and other surgical procedures.

KW - Cancer

KW - Chemokine receptors

KW - Chemokines

KW - CTL

KW - Cytokines

KW - Dendritic cells

KW - IL-12

KW - Immunotherapy

KW - NK

KW - Th1

KW - Treg

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=79961170539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961170539&partnerID=8YFLogxK

U2 - 10.1007/s12026-011-8224-z

DO - 10.1007/s12026-011-8224-z

M3 - Article

C2 - 21717071

AN - SCOPUS:79961170539

VL - 50

SP - 235

EP - 247

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 2-3

ER -